{"id":48402,"date":"2022-09-14T22:01:40","date_gmt":"2022-09-14T20:01:40","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/"},"modified":"2022-09-14T22:01:40","modified_gmt":"2022-09-14T20:01:40","slug":"ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/","title":{"rendered":"Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen"},"content":{"rendered":"
\n

\nVentria\u2019s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation<\/i>\n<\/p>\n

<\/a><\/p>\n

JUNCTION CITY, Kan.–(BUSINESS WIRE)–#biotech<\/a>—Ventria Bioscience Inc. (Ventria)<\/a> today announced that the United States International Trade Commission (ITC)<\/a> completed its review of Administrative Law Judge McNamara\u2019s previous determination and affirmed the prior ruling that Wuhan Healthgen and its distributors violated Section 337 by importing into the United States products that infringe Ventria\u2019s patent and which were marketed and sold without being labeled as originating from China. The ITC issued exclusion orders and cease-and-desist orders which prohibit the importation and distribution of Wuhan Healthgen products that infringe Ventria\u2019s patent and\/or fail to conspicuously designate China as the country of origin.\n<\/p>\n

\nThe ITC review once again confirmed the validity of Ventria\u2019s patent related to recombinant albumin proteins manufactured using plant biotechnology. This was the third such review of Ventria\u2019s patent in this area of innovation. Last month, the U.S. Patent and Trademark Office (PTO) denied Wuhan Healthgen\u2019s request for an inter partes review of the patent, on the merits. And in her April decision, Judge McNamara upheld the validity of Ventria\u2019s patent after a weeklong trial.\n<\/p>\n

\n\u201cThe ITC affirmed the validity of the \u2019951 patent, affirmed that Ventria satisfies the domestic-industry requirement of Section 337, and has excluded Wuhan Healthgen\u2019s infringing products from the U.S. market,\u201d said Beau Jackson of Husch Blackwell, ITC counsel for Ventria. \u201cThis is an important victory, and we are also pleased the ITC imposed cease and desist orders against Healthgen\u2019s distributors for concealing the country-of-origin of these products,\u201d he continued.\n<\/p>\n

\n\u201cThis is a win for American innovation and it follows the recent win for Ventria at the PTO,\u201d said Crissa Seymour Cook of Hovey Williams, Ventria\u2019s intellectual property counsel. \u201cBiotechnology is a critical American industry,\u201d she continued. \u201cCompanies like Ventria make significant investments to develop new technologies and feel encouraged to continue their research and manufacturing when they know they can protect the results of their efforts through strong patents.\u201d\n<\/p>\n

\n\u201cVentria\u2019s ExpressTec platform is a breakthrough innovation that can help improve human health, longevity and quality of life,\u201d said Scott E. Deeter, CEO of Ventria. \u201cThis is only possible if the enormous investments in research convert into products that deliver a return on the research investment, and that is only possible if the creativity is protected from copycats who do not shoulder the trials and tribulations of the innovative process,\u201d said Mr. Deeter.\n<\/p>\n

\nSupporting documents:\n<\/p>\n

\nITC Letter to US Customs and Border Protection Instituting Exclusion Order<\/a>
<\/span>Letter from ITC Chairman Johanson to President Biden<\/a>
<\/span>Letter from ITC Chairman Johanson to Treasury Secretary Yellen<\/a>
Letter from ITC Chairman Johanson to USTR Ambassador Katherine Tai<\/a>
Letter from Kansas Governor Laura Kelly<\/a>
Letter from Colorado Governor Jared Polis<\/a>
Letter from US Senators from Kansas : Senator Moran & Senator Marshall<\/a>
Letter from US Senators from Colorado: Senator Bennet & Senator Hickenlooper<\/a>
Letter from Kansas Congressional Delegation: Ron Estes; Tracey Mann; Jake LaTurner<\/a>
Letter from Kansas Congresswoman Sharice Davids<\/a>
Letter from Kansas Attorney General Derek Schmidt<\/a>
Letter from Kansas Chamber CEO Alan Cobb<\/a>
Letter from BioKansas CEO Dr. Sonia Hall<\/a>
Letter from Colorado BioScience Association CEO Elyse Blazevich<\/a>
Letter from Coalition for a Prosperous America CEO Michael Stumo<\/a>\n<\/p>\n

\nAbout Ventria Bioscience Inc.<\/b>\n<\/p>\n

\nVentria Bioscience is a privately held biotechnology company whose vision is to improve human longevity and quality of life by developing and commercializing innovative medicines, functional food ingredients, cell-culture media components and biologic formulation excipients derived from its breakthrough plant biotechnology: ExpressTec. Ventria is the parent company of CuraVive (www.CuraVive.com<\/a>) and InVitria (www.InVitria.com<\/a>). More about Ventria\u2019s ExpressTec Click Here<\/a>.\n<\/p>\n

\nFor more information about Ventria Bioscience Inc. Click Here.<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia@Ventria.com<\/a>
1-800-916-8311\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Ventria\u2019s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation JUNCTION CITY, Kan.–(BUSINESS WIRE)–#biotech—Ventria Bioscience Inc. (Ventria) today announced that the United States International Trade Commission (ITC) completed its review of Administrative Law Judge McNamara\u2019s previous determination and affirmed the prior ruling that … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48402","6":"format-standard","7":"category-industry"},"yoast_head":"\nVentria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Ventria\u2019s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation JUNCTION CITY, Kan.–(BUSINESS WIRE)–#biotech—Ventria Bioscience Inc. (Ventria) today announced that the United States International Trade Commission (ITC) completed its review of Administrative Law Judge McNamara\u2019s previous determination and affirmed the prior ruling that ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-14T20:01:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220914005883\/en\/1571929\/21\/Ventria_Bioscience_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen\",\"datePublished\":\"2022-09-14T20:01:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/\"},\"wordCount\":650,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005883\\\/en\\\/1571929\\\/21\\\/Ventria_Bioscience_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/\",\"name\":\"Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005883\\\/en\\\/1571929\\\/21\\\/Ventria_Bioscience_Logo.jpg\",\"datePublished\":\"2022-09-14T20:01:40+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005883\\\/en\\\/1571929\\\/21\\\/Ventria_Bioscience_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220914005883\\\/en\\\/1571929\\\/21\\\/Ventria_Bioscience_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/","og_locale":"en_US","og_type":"article","og_title":"Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen - Pharma Trend","og_description":"Ventria\u2019s success in excluding unfairly traded imports secures its ability to continue to invest in the next generation of plant biotechnology innovation JUNCTION CITY, Kan.–(BUSINESS WIRE)–#biotech—Ventria Bioscience Inc. (Ventria) today announced that the United States International Trade Commission (ITC) completed its review of Administrative Law Judge McNamara\u2019s previous determination and affirmed the prior ruling that ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-14T20:01:40+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220914005883\/en\/1571929\/21\/Ventria_Bioscience_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen","datePublished":"2022-09-14T20:01:40+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/"},"wordCount":650,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220914005883\/en\/1571929\/21\/Ventria_Bioscience_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/","url":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/","name":"Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220914005883\/en\/1571929\/21\/Ventria_Bioscience_Logo.jpg","datePublished":"2022-09-14T20:01:40+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220914005883\/en\/1571929\/21\/Ventria_Bioscience_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220914005883\/en\/1571929\/21\/Ventria_Bioscience_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/ventria-bioscience-wins-exclusion-order-against-infringing-and-mislabled-products-from-wuhan-healthgen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Ventria Bioscience Wins Exclusion Order Against Infringing and Mislabled Products From Wuhan Healthgen"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48402"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48402\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}